AR069356A1 - Tratamiento de disfagia faringea oral - Google Patents

Tratamiento de disfagia faringea oral

Info

Publication number
AR069356A1
AR069356A1 ARP080105015A ARP080105015A AR069356A1 AR 069356 A1 AR069356 A1 AR 069356A1 AR P080105015 A ARP080105015 A AR P080105015A AR P080105015 A ARP080105015 A AR P080105015A AR 069356 A1 AR069356 A1 AR 069356A1
Authority
AR
Argentina
Prior art keywords
product
promoting
individual
agonist
vanilloid receptor
Prior art date
Application number
ARP080105015A
Other languages
English (en)
Inventor
Kevin Burke Miller
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40139229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of AR069356A1 publication Critical patent/AR069356A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Tea And Coffee (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un producto nutricional o medicinal liquido administrable por vía oral caracterizada porque comprende: al menos un agonista del receptor vainilloide 1 (VR-1) capaz de promover un reflejo de deglucion en un individuo. Reivindicacion 2: Un producto de hidratacion líquido administrable por vía oral caracterizada porque comprende: al menos un agonista del receptor vainilloide 1 (VR-1) capaz de promover un reflejo de deglucion en un individuo. Reivindicacion 3: Un producto alimenticio de textura modificada caracterizado porque comprende: al menos un agonista del receptor vainilloide 1 (VR-1) capaz de promover un reflejo de deglucion en un individuo. Reivindicacion 4: El producto de la reivindicacion 1, 2, o 3, caracterizado porque al menos un agonista de VR-1 no es pungente. Reivindicacion 5: El producto de la reivindicacion 1, 2, o 3, caracterizada porque al menos un agonista de VR-1 se selecciona del grupo que consiste en: capsaicina, capsiato, dihidrocapsaicina, dihidrocapsiato nordihidrocapsaicina, nordihidrocapsiato, homocapsaicina, homodihidrocapsaicina, vanillilamida de ácido n-nonanoico (VNA), anandamida, resiniferatoxina y olvanilo. Reivindicacion 6: El producto de la reivindicacion 1, 2, o 3, caracterizado porque además comprende al menos uno de los siguientes: una proteína, una fibra soluble, una fibra insoluble, un ácido graso, una vitamina, un mineral, un azucar, un carbohidrato, un agente saborizante, un medicamento y un agente terapéutico.
ARP080105015A 2007-11-19 2008-11-18 Tratamiento de disfagia faringea oral AR069356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98893007P 2007-11-19 2007-11-19
US2289908P 2008-01-23 2008-01-23

Publications (1)

Publication Number Publication Date
AR069356A1 true AR069356A1 (es) 2010-01-13

Family

ID=40139229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105015A AR069356A1 (es) 2007-11-19 2008-11-18 Tratamiento de disfagia faringea oral

Country Status (19)

Country Link
US (1) US8871281B2 (es)
EP (2) EP2222289B1 (es)
JP (2) JP2011504172A (es)
CN (1) CN101848709A (es)
AR (1) AR069356A1 (es)
AU (1) AU2008326640C1 (es)
BR (1) BRPI0819342A2 (es)
CA (1) CA2705836C (es)
CL (1) CL2008003438A1 (es)
DK (1) DK2222289T3 (es)
ES (1) ES2430043T3 (es)
HK (1) HK1142010A1 (es)
MX (1) MX2010005465A (es)
PT (1) PT2222289E (es)
RU (2) RU2481829C2 (es)
SG (1) SG188167A1 (es)
TW (1) TWI426899B (es)
WO (1) WO2009067296A1 (es)
ZA (1) ZA201004333B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2430043T3 (es) 2007-11-19 2013-11-18 Nestec S.A. Tratamiento de la disfagia faríngea oral
WO2014124201A1 (en) 2013-02-08 2014-08-14 General Mills, Inc. Reduced sodium food products
EP3024450B1 (en) 2013-07-22 2019-08-21 Société des Produits Nestlé S.A. Compositions and methods using tiglic aldehyde
JP6879297B2 (ja) * 2016-04-13 2021-06-02 味の素株式会社 加齢に伴う身体機能低下もしくは身体機能障害、または加齢に伴う精神機能低下もしくは精神機能障害の抑制または改善用組成物
CN108142940B (zh) * 2018-02-05 2021-05-14 中山大学附属第三医院（中山大学肝脏病医院） 一种促吞咽软片及其制备方法
JP7519359B2 (ja) * 2018-12-24 2024-07-19 ソレント・セラピューティクス・インコーポレイテッド レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法
RU2714177C1 (ru) * 2019-07-23 2020-02-12 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ лечения крикофарингеальной недостаточности и восстановления функции глотания

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07274915A (ja) 1994-03-31 1995-10-24 Taiyo Kagaku Co Ltd 柔軟性容器入りゼリー様飲料
JP3345744B2 (ja) 1998-03-04 2002-11-18 森永製菓株式会社 エステル結合を有する新規なカプサイシノイド様物質
US20020019444A1 (en) * 2000-05-08 2002-02-14 Edward Hogestatt Anandamide and structurally related lipids as vanilloid receptor modulators
US7638150B2 (en) * 2002-08-02 2009-12-29 Simply Thick Llp Process for preparing concentrate thickener compositions
US20030082249A1 (en) * 2001-10-26 2003-05-01 Ovation Pharmaceuticals Compositions containing capsaicin and its derivatives, and their use in treating mucositis
GB0221157D0 (en) 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
CN100431553C (zh) 2002-12-26 2008-11-12 株式会社山田养蜂场本社 改善咽下障碍用组合物
EP2070551B1 (en) 2003-01-31 2013-01-16 Simply Thick LLC Process for producing thickened beverages for dysphagia
JP4931128B2 (ja) * 2003-04-10 2012-05-16 ニューロジェシックス， インコーポレイテッド Ｔｒｐｖ１アゴニストの投与のための方法および組成物
US20060182825A1 (en) * 2005-02-11 2006-08-17 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and compounds for the treatment of obesity and obesity-related disorders
JP4526472B2 (ja) * 2005-12-02 2010-08-18 仁敬 越久 嚥下障害治療装置
CA2641950A1 (en) * 2006-02-10 2007-08-23 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
EP2011494B1 (en) * 2006-04-24 2013-08-21 Ajinomoto Co., Inc. Agent for amelioration of dysphagia, and pharmaceutical or food composition comprising the same
ES2430043T3 (es) 2007-11-19 2013-11-18 Nestec S.A. Tratamiento de la disfagia faríngea oral

Also Published As

Publication number Publication date
TW200934479A (en) 2009-08-16
SG188167A1 (en) 2013-03-28
TWI426899B (zh) 2014-02-21
US20110028382A1 (en) 2011-02-03
RU2010125285A (ru) 2011-12-27
AU2008326640B2 (en) 2012-08-23
CL2008003438A1 (es) 2010-01-11
AU2008326640A1 (en) 2009-05-28
MX2010005465A (es) 2010-06-02
US8871281B2 (en) 2014-10-28
EP2222289A1 (en) 2010-09-01
BRPI0819342A2 (pt) 2015-05-19
CN101848709A (zh) 2010-09-29
EP2222289B1 (en) 2013-08-28
RU2481829C2 (ru) 2013-05-20
RU2013103032A (ru) 2014-07-27
JP2013056893A (ja) 2013-03-28
EP2578213A1 (en) 2013-04-10
ES2430043T3 (es) 2013-11-18
WO2009067296A1 (en) 2009-05-28
DK2222289T3 (da) 2013-10-07
AU2008326640C1 (en) 2013-07-04
PT2222289E (pt) 2013-09-30
JP2011504172A (ja) 2011-02-03
CA2705836C (en) 2014-06-10
CA2705836A1 (en) 2009-05-28
ZA201004333B (en) 2011-12-28
HK1142010A1 (en) 2010-11-26

Similar Documents

Publication Publication Date Title
AR069356A1 (es) Tratamiento de disfagia faringea oral
Donati Zeppa et al. Mutual interactions among exercise, sport supplements and microbiota
WO2011152726A8 (en) Pre-thickened compact liquid nutritional composition for dysphagia patients
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
ES2571856T3 (es) Uso de composiciones nutricionales para prevenir la adiposidad visceral
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
ES2547122T3 (es) Composición nutricional de baja concentración
CL2013003003A1 (es) Uso de fórmula infantil que comprende al menos una fuente de proteínas, una fuente de lípidos, una fuente de carbohidratos, con 1,6-1,85 g/100 kcal que sirve para preparar un medicamento útil en la prevención de la presión sanguínea elevada o de las enfermedades cardiovasculares.
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos
Jiang et al. Early enteral nutrition for upper digestive tract malformation in neonates
Casas et al. Adapted ice cream as a nutritional supplement in cancer patients: impact on quality of life and nutritional status
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
AR063891A1 (es) Composicion para ser usada en productos alimenticios, preparados nutricionales, nutraceuticos y farmaceuticos
CO2017006985A2 (es) Producto de administración oral
WO2011137322A3 (en) Methods and compositions for treating celiac disease
Kaur et al. Innate antioxidant activity of some traditional formulations
Bele et al. An approach to a Nutraceutical
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
NZ712924A (en) Use of a dietary fibre supplement in a food formulation
CL2020002369A1 (es) Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina
JP2008017813A (ja) 酢を含有する錠剤食品
Mahdinejadiani et al. An Evaluation the Effect of Glycyrrhetinic and Glycyrrhizic Acids Derived‎ from Licorice Extract on Gastric Cancer Cell Lines
Kan Therapeutic effect of a chitin oligosaccharide mixture by per os administration on human cancer
TH171960A (th) องค์ประกอบในรูปอนุภาคที่ช่วยแตกตัวซึ่งประกอบด้วยไมโครไฟบริลเลเทดเซลลูโลส

Legal Events

Date Code Title Description
FA Abandonment or withdrawal